Please assess the completion status of the following clinical trial:

Trial Title: Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed supratentorial anaplastic astrocytoma or glioblastoma~* Age \> 65~* Karnofsky performance score \> 60%~* Neutrophilic granulocyte count \> 1500/µl~* Platelet count \> 100 000/µl~* Hemoglobin \> 10 g/dl~* Serum creatinine \< 1.5 times the lab's upper normal limit~* AST or ALT \< 3 times the lab's upper normal limit~* Alkaline phosphatase \< 3 times the lab's upper normal limit~* No previous systemic chemotherapy~* No previous radiotherapy to the brain~* Written consent~Exclusion Criteria:~* Serious medical or neurological condition with a poor prognosis~* HIV infection~* Second cancer requiring radiotherapy or chemotherapy (contact the study coordinat if necessary)~* Hypersensitivity to temozolomide~* Conditions associated with regular vomiting that might affect oral administration of the drugs~* Psychological, familial, social or geographical circumstances with major implications for compliance with the study visit schedule~* Patient was taking part in other intervention studies within a month of starting this study

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiotherapy (Type: ACTIVE_COMPARATOR): 6 weeks standard partial brain treatment.
- Temozolomide (Type: EXPERIMENTAL): Temozolomide in a one week on/one week off schedule per Wick et al. 2004 and A. Wick et al. 2007

Based on this trial design, predict the completion outcome and termination type (if applicable).